ClinicalTrials.gg
CompletedNCT02352948ARCTICUpdated Jul 26, 2024Results posted

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

A Phase 3 interventional study of MEDI4736 (durvalumab) and Vinorelbine in Non - Small Cell Lung Cancer NSCLC, sponsored by AstraZeneca. Completed at 203 sites in 26 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
597
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
11th of 94
597 · median 74
Started
2015
with 6 others
Phase 3
17 of 94
3 open now
Registered
10th of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment, is one of 7 that started in 2015, is one of 17 in phase 3, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 (durvalumab) plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®)

Read the detailed description

The study has an umbrella design with 2 sub-studies: sub-study A (randomizing patients with PD-L1 positive tumours 1:1 into MEDI4736 (durvalumab) vs. Standard of Care) and sub-study B (randomizing patients with PD-L1 negative tumours 2:3:1:2 into MEDI4736 (durvalumab) vs. MEDI4736 (durvalumab) plus tremelimumab vs. tremelimumab vs. Standard of Care. The two substudies may have different durations of recruitment periods due to differences in patient population (PD-L1 expression). They may not run concurrently with start and completion of recruitment potentially occurring at different time points.

03

Conditions studied

  • Non - Small Cell Lung Cancer NSCLC
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged at least 18 years
  • Documented evidence of NSCLC (Stage IIIB/ IV disease)
  • Disease progression or recurrence after both a platinum-based chemotherapy regimen and at least 1 additional regimen for treatment of NSCLC
  • World Health Organization (WHO) Performance Status of 0 or 1
  • Estimated more than 12 weeks

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any or anti-PD-L1 antibody or anti-CTLA4
  • or spinal cord compression unless asymptomatic, treated and stable (not requiring )
  • Active or prior documented disease within the past 2 years
  • Evidence of severe or uncontrolled systemic disease, including active bleeding diatheses or active infections including , C and
  • Any unresolved toxicity (Common Terminology Criteria of Adverse Events) >Grade 2 from previous anti-cancer therapy
  • Known EGFR TK activating mutations or ALK rearrangements
  • Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1
  • Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
597 participants (actual)

Study arms

  • Experimental
    MEDI4736 (durvalumab) monotherapy in Sub-study A

    MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.

    Drug: MEDI4736 (durvalumab)

  • Active comparator
    Standard of Care in Sub-study A

    Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.

    Drug: Vinorelbine · Drug: Gemcitabine · Drug: Erlotinib

  • Experimental
    MEDI4736 (durvalumab) + tremelimumab in Sub-study B

    MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.

    Drug: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)

  • Active comparator
    Standard of Care in Sub-study B

    Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.

    Drug: Vinorelbine · Drug: Gemcitabine · Drug: Erlotinib

  • Experimental
    MEDI4736 (durvalumab) monotherapy in Sub-study B

    MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.

    Drug: MEDI4736 (durvalumab)

  • Experimental
    tremelimumab in Sub-study B

    tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.

    Drug: tremelimumab (anti-CTLA4)

Interventions

  • MEDI4736 (durvalumab) treatment by intravenous infusion

  • Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.

  • Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.

  • Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration

  • DrugMEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)

    Drug page: Durvalumab

    MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion

  • tremelimumab (anti-CTLA4) treatment by intravenous infusion

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    The OS was defined as the time from the date of randomization until death due to any cause.

    Time frame: From randomization (Day 1) until death due to any cause, approximately 36 months

  2. Progression-Free Survival (PFS)

    The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to response evaluation criteria in solid tumours (RECIST) version 1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion

    Time frame: Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.

Secondary outcomes

  1. OS, Contribution of the Components Analysis of Sub-study B

    The OS was defined as the time from the date of randomization until death due to any cause.

    Time frame: From randomization (Day 1) until death due to any cause, approximately 36 months

  2. Percentage of Participants Alive at 12 Months (OS12)

    The OS12 was defined as the percentage of participants who were alive at 12 months after randomisation per Kaplan-Meier estimate of OS at 12 months.

    Time frame: From randomization (Day 1) up to 12 months

  3. PFS, Contribution of the Components Analysis of Sub-study B

    The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion

    Time frame: Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.

  4. Objective Response Rate (ORR)

    The ORR was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) among ITT participants who had measurable disease at baseline. CR was defined as disappearance of all target lesions (any pathological lymph nodes selected as target lesions must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum of diameters as long as criteria for PD are not met). The ORR was measured using Investigator assessments according to RECIST v1.1.

    Time frame: Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.

  5. Duration of Response (DoR)

    The DoR was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The DoR was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion

    Time frame: Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.

  6. Percentage of Participants Alive and Progression Free at 6 Months (APF6)

    The APF6 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 6 months after randomization per Kaplan-Meier estimate of PFS at 6 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion

    Time frame: Tumour scans performed at baseline then every ~8 weeks up to 6 months

  7. Percentage of Participants Alive and Progression Free at 12 Months (APF12)

    The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 12 months after randomization per Kaplan-Meier estimate of PFS at 12 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion

    Time frame: Tumour scans performed at baseline then every ~8 weeks up to 12 months.

  8. Time From Randomisation to Second Progression (PFS2) of Sub-study B

    The PFS2 was defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the PFS endpoint or death and determined by local standard clinical practice and have included any of the following: objective radiological, symptomatic progression, or death. PFS2 was reported for sub-study B only.

    Time frame: Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until first progression. Disease then assessed per local practice until 2nd progression. Assessed up to a maximum of approximately 3 years.

07

Results

Posted Apr 16, 2019

Participant flow

This study was divided into 2 parts, sub-study A (82 centers across Europe, Asia, and North America) and sub-study B (149 centers across Europe, Asia, North America, and South America) conducted between 13 January 2015 and 09 February 2018 (data cut-off date).

Participant flow — Overall Study
MilestoneSub-study A: DurvalumabSub-study A: Standard of Care (SoC)Sub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: Tremelimumab
Started626417411811760
Received treatment626317311011760
Completed study treatment150360234
Completed13545192911
Not completed4959129998849
Withdrew: Death4748114747744
Withdrew: Lost to follow-up102121
Withdrew: Withdrawal by subject110112394
Withdrew: Eligibility criteria not fulfilled010100
Withdrew: Other002000

Outcome measures

PrimaryOverall Survival (OS)

The OS was defined as the time from the date of randomization until death due to any cause.

Time frame:
From randomization (Day 1) until death due to any cause, approximately 36 months
Reported as:
Median · months
Overall Survival (OS)
monthsSub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoC
Overall Survival (OS)11.7 (8.2 to 17.4)6.8 (4.9 to 10.2)11.5 (8.7 to 14.1)8.7 (6.5 to 11.7)
Statistical analysis
  • Sub-study A: Durvalumab vs Sub-study A: SoC · Hazard ratio (hr): 0.63 · 95% CI 0.42 to 0.93Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: SoC · Log Rank · p = 0.109 · Hazard ratio (hr): 0.80 · 95% CI 0.61 to 1.05Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.
PrimaryProgression-Free Survival (PFS)

The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to response evaluation criteria in solid tumours (RECIST) version 1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion

Time frame:
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsSub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoC
Progression-Free Survival (PFS)3.8 (1.9 to 5.6)2.2 (1.9 to 3.7)3.5 (2.3 to 4.6)3.5 (1.9 to 3.9)
Statistical analysis
  • Sub-study A: Durvalumab vs Sub-study A: SoC · Hazard ratio (hr): 0.71 · 95% CI 0.49 to 1.04Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: SoC · Log Rank · p = 0.056 · Hazard ratio (hr): 0.77 · 95% CI 0.59 to 1.01Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.
SecondaryOS, Contribution of the Components Analysis of Sub-study B

The OS was defined as the time from the date of randomization until death due to any cause.

Time frame:
From randomization (Day 1) until death due to any cause, approximately 36 months
Reported as:
Median · months
OS, Contribution of the Components Analysis of Sub-study B
monthsSub-study B: Durvalumab+TremelimumabSub-study B: DurvalumabSub-study B: Tremelimumab
OS, Contribution of the Components Analysis of Sub-study B11.5 (8.7 to 14.1)10.0 (7.1 to 13.2)6.9 (3.9 to 13.2)
Statistical analysis
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: Durvalumab · Log Rank · p = 0.885 · Hazard ratio (hr): 0.98 · 95% CI 0.74 to 1.30Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: Tremelimumab · Log Rank · p = 0.153 · Hazard ratio (hr): 0.78 · 95% CI 0.56 to 1.11Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.
SecondaryPercentage of Participants Alive at 12 Months (OS12)

The OS12 was defined as the percentage of participants who were alive at 12 months after randomisation per Kaplan-Meier estimate of OS at 12 months.

Time frame:
From randomization (Day 1) up to 12 months
Reported as:
Number · percentage of participants
Percentage of Participants Alive at 12 Months (OS12)
percentage of participantsSub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: Tremelimumab
Percentage of Participants Alive at 12 Months (OS12)49.3 (36.3 to 61.0)31.3 (20.2 to 43.0)49.5 (41.7 to 56.7)38.8 (29.9 to 47.7)43.6 (34.4 to 52.4)41.2 (28.7 to 53.3)
Statistical analysis
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: SoC · z-test · p = 0.063 (The z-test statistic is the ratio of log-transformed ratio of the cumulative hazards in the 2 treatment arms divided by square root of the variance.)The variance is estimated using the delta method and Greenwood's formula.
SecondaryPFS, Contribution of the Components Analysis of Sub-study B

The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion

Time frame:
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Reported as:
Median · months
PFS, Contribution of the Components Analysis of Sub-study B
monthsSub-study B: Durvalumab+TremelimumabSub-study B: DurvalumabSub-study B: Tremelimumab
PFS, Contribution of the Components Analysis of Sub-study B3.5 (2.3 to 4.6)3.1 (1.9 to 3.7)2.1 (1.8 to 3.2)
Statistical analysis
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: Durvalumab · Log Rank · p = 0.282 · Hazard ratio (hr): 0.87 · 95% CI 0.68 to 1.12Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: Tremelimumab · Log Rank · p = 0.011 · Hazard ratio (hr): 0.67 · 95% CI 0.49 to 0.92Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.
SecondaryObjective Response Rate (ORR)

The ORR was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) among ITT participants who had measurable disease at baseline. CR was defined as disappearance of all target lesions (any pathological lymph nodes selected as target lesions must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum of diameters as long as criteria for PD are not met). The ORR was measured using Investigator assessments according to RECIST v1.1.

Time frame:
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsSub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: Tremelimumab
Objective Response Rate (ORR)35.512.514.96.815.46.7
Statistical analysis
  • Sub-study A: Durvalumab vs Sub-study A: SoC · Odds ratio (or): 3.87 · 95% CI 1.61 to 10.10The analysis was performed using logistic regression adjusting for SoC therapy (gemcitabine/vinorelbine versus erlotinib) and histology (squamous versus all other histology types), with 95% CI calculated by profile likelihood.
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: SoC · Regression, Logistic · p = 0.037 · Odds ratio (or): 2.43 · 95% CI 1.10 to 5.94The analysis was performed using logistic regression adjusting for SoC therapy (gemcitabine/vinorelbine versus erlotinib) and histology (squamous versus all other histology types), with 95% CI calculated by profile likelihood.
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: Durvalumab · Regression, Logistic · p = 0.923 · Odds ratio (or): 0.97 · 95% CI 0.51 to 1.89The analysis was performed using logistic regression adjusting for SoC therapy (gemcitabine/vinorelbine versus erlotinib) and histology (squamous versus all other histology types), with 95% CI calculated by profile likelihood.
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: Tremelimumab · Regression, Logistic · p = 0.109 · Odds ratio (or): 2.46 · 95% CI 0.91 to 8.61The analysis was performed using logistic regression adjusting for SoC therapy (gemcitabine/vinorelbine versus erlotinib) and histology (squamous versus all other histology types), with 95% CI calculated by profile likelihood.
SecondaryDuration of Response (DoR)

The DoR was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The DoR was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion

Time frame:
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Reported as:
Median · months
Duration of Response (DoR)
monthsSub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: Tremelimumab
Duration of Response (DoR)9.5 (3.0 to 17.8)4.8 (1.9 to 7.6)12.2 (6.5 to NA)10.8 (5.6 to 12.2)10.0 (4.0 to NA)4.7 (2.9 to NA)
SecondaryPercentage of Participants Alive and Progression Free at 6 Months (APF6)

The APF6 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 6 months after randomization per Kaplan-Meier estimate of PFS at 6 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion

Time frame:
Tumour scans performed at baseline then every ~8 weeks up to 6 months
Reported as:
Number · percentage of participants
Percentage of Participants Alive and Progression Free at 6 Months (APF6)
percentage of participantsSub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: Tremelimumab
Percentage of Participants Alive and Progression Free at 6 Months (APF6)35.5 (23.9 to 47.3)24.1 (14.1 to 35.6)31.5 (24.6 to 38.7)27.6 (19.0 to 36.7)27.2 (19.4 to 35.6)14.5 (6.9 to 24.9)
SecondaryPercentage of Participants Alive and Progression Free at 12 Months (APF12)

The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 12 months after randomization per Kaplan-Meier estimate of PFS at 12 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion

Time frame:
Tumour scans performed at baseline then every ~8 weeks up to 12 months.
Reported as:
Number · percentage of participants
Percentage of Participants Alive and Progression Free at 12 Months (APF12)
percentage of participantsSub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: Tremelimumab
Percentage of Participants Alive and Progression Free at 12 Months (APF12)19.4 (10.7 to 30.0)9.9 (3.8 to 19.3)20.6 (14.7 to 27.1)8.0 (3.4 to 15.2)15.0 (9.1 to 22.3)7.3 (2.4 to 16.0)
SecondaryTime From Randomisation to Second Progression (PFS2) of Sub-study B

The PFS2 was defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the PFS endpoint or death and determined by local standard clinical practice and have included any of the following: objective radiological, symptomatic progression, or death. PFS2 was reported for sub-study B only.

Time frame:
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until first progression. Disease then assessed per local practice until 2nd progression. Assessed up to a maximum of approximately 3 years.
Reported as:
Median · months
Time From Randomisation to Second Progression (PFS2) of Sub-study B
monthsSub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: Tremelimumab
Time From Randomisation to Second Progression (PFS2) of Sub-study B9.1 (6.6 to 12.3)6.7 (4.7 to 8.9)8.0 (6.3 to 10.0)5.7 (3.2 to 10.0)
Statistical analysis
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: SoC · Log Rank · p = 0.002 · Hazard ratio (hr): 0.65 · 95% CI 0.49 to 0.85Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.

Adverse events

Collected over From signature of informed consent up to 90 days after the last dose of durvalumab and/or tremelimumab and 30 days after the last dose of SoC, approximately 15 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sub-study A: Durvalumab48/62 (77.4%)23/62 (37.1%)52/62 (83.9%)
Sub-study A: SoC55/64 (85.9%)16/63 (25.4%)59/63 (93.7%)
Sub-study B: Durvalumab+Tremelimumab118/174 (67.8%)65/173 (37.6%)139/173 (80.3%)
Sub-study B: SoC90/118 (76.3%)28/110 (25.5%)100/110 (90.9%)
Sub-study B: Durvalumab83/117 (70.9%)36/117 (30.8%)99/117 (84.6%)
Sub-study B: Tremelimumab46/60 (76.7%)23/60 (38.3%)48/60 (80%)
Most frequent serious events
Showing 10 of 133
Most frequent serious events
EventSub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: Tremelimumab
DiarrhoeaGastrointestinal disorders0/620/633/1730/1101/1177/60
ColitisGastrointestinal disorders1/620/633/1730/1100/1175/60
Febrile neutropeniaBlood and lymphatic system disorders0/625/630/1730/1100/1170/60
PneumoniaInfections and infestations4/623/637/1732/1102/1172/60
Pleural effusionRespiratory, thoracic and mediastinal disorders3/620/632/1730/1101/1172/60
DyspnoeaRespiratory, thoracic and mediastinal disorders1/620/637/1732/1102/1170/60
Clostridium difficile colitisInfections and infestations0/620/630/1730/1100/1172/60
Respiratory failureRespiratory, thoracic and mediastinal disorders1/620/631/1731/1101/1172/60
SepsisInfections and infestations2/620/630/1730/1101/1170/60
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/620/635/1731/1101/1171/60
Most frequent other events
Showing 10 of 50
Most frequent other events
EventSub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: Tremelimumab
Decreased appetiteMetabolism and nutrition disorders16/6220/6334/17323/11027/11712/60
AnaemiaBlood and lymphatic system disorders5/6217/6317/17327/11011/1175/60
DiarrhoeaGastrointestinal disorders9/628/6336/17318/11025/11716/60
ConstipationGastrointestinal disorders13/6215/6314/17311/11015/1174/60
NauseaGastrointestinal disorders11/6215/6328/17322/11020/11711/60
PruritusSkin and subcutaneous tissue disorders7/622/6328/1735/11011/11714/60
FatigueGeneral disorders10/6210/6325/17324/11022/1174/60
PyrexiaGeneral disorders9/626/6320/17323/11012/1176/60
AstheniaGeneral disorders6/628/6331/17317/11016/1179/60
DyspnoeaRespiratory, thoracic and mediastinal disorders11/629/6325/17315/11016/1176/60

Baseline characteristics

Sub-study A and B: Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.

Age, Customized
Age, Customized(Participants)Sub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: TremelimumabTotal
<50 years31116813455
>=50 to <65 years312579495227263
>=65 to <75 years242164503924222
>=75 years47151113555
Sex: Female, Male
Sex: Female, Male(Participants)Sub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: TremelimumabTotal
Female201659374421197
Male4248115817339398
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sub-study A: DurvalumabSub-study A: SoCSub-study B: Durvalumab+TremelimumabSub-study B: SoCSub-study B: DurvalumabSub-study B: TremelimumabTotal
American Indian or Alaska Native0000000
Asian222341413416177
Native Hawaiian or Other Pacific Islander0000000
Black or African American0132219
White4040129747943405
Unknown or Not Reported0000101
Other0011103
08

Study locations

203 sites
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Port Saint Lucie, Florida 34952, United States
  • Research Site
    Saint Petersburg, Florida 33705, United States
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Waterloo, Iowa 50701, United States
  • Research Site
    Ashland, Kentucky 41101, United States
  • Research Site
    Rockville, Maryland 20850, United States
  • Research Site
    Battle Creek, Michigan 49017, United States
  • Research Site
    Saint Louis, Missouri 63156, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Bronx, New York 10461-2375, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    New York, New York 10011, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Pinehurst, North Carolina 28374, United States
  • Research Site
    Cincinnati, Ohio 45242, United States
  • Research Site
    West Chester, Ohio 45069, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Salt Lake City, Utah 84106, United States
  • Research Site
    Spokane, Washington 99208, United States
  • Research Site
    Murdoch, 6150, Australia
  • Research Site
    Port Macquarie, 2444, Australia
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Libramont-Chevigny, 6800, Belgium
  • Research Site
    Mons, 7000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Yvoir, 5530, Belgium
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Varna, 9010, Bulgaria
  • Research Site
    Moncton, New Brunswick E1C 6Z8, Canada
  • Research Site
    Saint John, New Brunswick E2L 4L2, Canada
  • Research Site
    Santiago, 7500000, Chile
  • Research Site
    Santiago, 8420383, Chile
  • Research Site
    Temuco, 4810469, Chile
  • Research Site
    Nova Ves pod Plesi, 262 04, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Praha 5, 150 06, Czechia
  • Research Site
    Avignon Cedex 9, 84918, France
  • Research Site
    Bayonne, 64100, France
  • Research Site
    Brest Cedex, 29609, France
  • Research Site
    Creteil, 94010, France
  • Research Site
    Le Mans, 72000, France
  • Research Site
    Marseille Cedex 20, 13915, France
  • Research Site
    Montpellier Cedex, 34295, France
  • Research Site
    Nice, 06100, France
  • Research Site
    Pau Cedex, 64046, France
  • Research Site
    Saint Herblain, 44805, France
  • Research Site
    Toulon, 83100, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Berlin, 10967, Germany
  • Research Site
    Berlin, 12351, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Halle, 06120, Germany
  • Research Site
    Hamburg, 22081, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Homburg, 66421, Germany
  • Research Site
    Köln, 51109, Germany
  • Research Site
    Löwenstein, 74245, Germany
  • Research Site
    Regensburg, 93053, Germany
  • Research Site
    Trier, 54290, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Villingen-Schwenningen, 78052, Germany
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Thessaloniki, 54645, Greece
  • Research Site
    Thessaloniki, 57010, Greece
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Miskolc, 3529, Hungary
  • Research Site
    Törökbálint, 2045, Hungary
  • Research Site
    Zalaegerszeg, 8000, Hungary
  • Research Site
    Zalaegerszeg, 8900, Hungary
  • Research Site
    Tel Hashomer, 52621, Israel
  • Research Site
    Aviano, 33081, Italy
  • Research Site
    Candiolo, 10060, Italy
  • Research Site
    Catania, 95123, Italy
  • Research Site
    Cremona, 26100, Italy
  • Research Site
    Genova, 16100, Italy
  • Research Site
    Lucca, 55100, Italy
  • Research Site
    Milano, 20132, Italy
  • Research Site
    Milano, 20133, Italy
  • Research Site
    Milano, 20141, Italy
  • Research Site
    Monza, 20900, Italy
  • Research Site
    Napoli, 80131, Italy

Showing the first 100 of 203 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Martin ML, Correll J, Walding A, Ryden A. How patients being treated for non-small cell lung cancer value treatment benefit despite side effects. Qual Life Res. 2022 Jan;31(1):135-146. doi: 10.1007/s11136-021-02882-6. Epub 2021 May 31. PubMed 34056687 ↗
  • Planchard D, Reinmuth N, Orlov S, Fischer JR, Sugawara S, Mandziuk S, Marquez-Medina D, Novello S, Takeda Y, Soo R, Park K, McCleod M, Geater SL, Powell M, May R, Scheuring U, Stockman P, Kowalski D. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Ann Oncol. 2020 May;31(5):609-618. doi: 10.1016/j.annonc.2020.02.006. Epub 2020 Feb 20. PubMed 32201234 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Feb 2018, 36 months.

Results were first posted in Apr 2019, 1 year 2 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 36 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2015
First posted
Feb 2, 2015
StartActual
Jan 13, 2015
Primary completionActual
Feb 9, 2018
CompletionActual
Aug 30, 2023
Results first posted
Apr 16, 2019
Last update
Jul 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02352948
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 2, 2015
Start date
Jan 13, 2015
Primary completion
Feb 9, 2018
Completion
Aug 30, 2023
Results posted
Apr 16, 2019
Last update
Jul 26, 2024

Study contacts

Paul Stockman, MBChB, PhD
study director · AstraZeneca

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion